| Literature DB >> 23899833 |
Hanita Omar1, Najihah Mohd Hashim, Asdren Zajmi, Noraziah Nordin, Siddiq Ibrahim Abdelwahab, Ainnul Hamidah Syahadah Azizan, A Hamid A Hadi, Hapipah Mohd Ali.
Abstract
The oxoaporphine alkaloid lysicamine (1), and three proaporphine alkaloids, litsericinone (2), 8,9,11,12-tetrahydromecambrine (3) and hexahydromecambrine A (4) were isolated from the leaves of Phoebe grandis (Nees) Merr. (Lauraceae). Compounds 2 and 3 were first time isolated as new naturally occurring compounds from plants. The NMR data for the compounds 2-4 have never been reported so far. Compounds 1 and 2 showed significant cytotoxic activity against a MCF7 (human estrogen receptor (ER+) positive breast cancer) cell line with IC₅₀ values of 26 and 60 µg/mL, respectively. Furthermore, in vitro cytotoxic activity against HepG2 (human liver cancer) cell line was evaluated for compounds 1-4 with IC₅₀ values of 27, 14, 81 and 20 µg/mL, respectively. Lysicamine (1) displayed strong antibacterial activity against Bacillus subtilis (B145), Staphylococcus aureus (S1434) and Staphylococus epidermidis (a clinically isolated strain) with inhibition zones of 15.50 ± 0.57, 13.33 ± 0.57 and 12.00 ± 0.00 mm, respectively. However, none of the tested pathogenic bacteria were susceptible towards compounds 2 and 3.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23899833 PMCID: PMC6270335 DOI: 10.3390/molecules18088994
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Alkaloids 1–4 isolated from Phoebe grandis (Nees) Merr. (Lauraceae).
13C-NMR (150 MHz), 1H-NMR (600 MHz) and HMBC spectral data of litsericinone, (2) in CDCl3 (δ in ppm, J in Hz).
| Position | 13C (δ, CDCl3) | Type | 1H ( | HMBC (2 |
|---|---|---|---|---|
| 1 | 148.9 | Cq | - | |
| 1a | 141.1 | Cq | - | |
| 1b | 123.9 | Cq | - | |
| 2 | 141.1 | Cq | - | |
| 3 | 106.9 | CH | 6.51 s | C1, C1a, C2, C4 |
| 3a | 126.7 | Cq | - | |
| 4 | 25.1 | CH2 | 2.87 m (ax) | C3, C1b, C1a |
| 2.75 m (eq) | C3, C1b, C1a | |||
| 5 | 43.9 | CH2 | 3.55 m (ax) | C4, C6a, C1b |
| 3.16 m (eq) | C4, C6a | |||
| 6a | 56.8 | CH | 4.26 dd | C5, C7 |
| ( | ||||
| 7 | 44.1 | CH2 | 2.73 m (ax) | C3, C3a, C1a |
| 1.87 m (eq) | C12, C7a, C6a | |||
| 7a | 46.2 | Cq | - | - |
| 8 | 38.5 | CH2 | 2.68 m (ax) | C10 |
| 2.41 m (eq) | C9, C7a, C10 | |||
| 9 | 36.2 | CH2 | 2.50 m (ax) | C8, C7a, C10 |
| 1.91 m (eq) | C11, C7a, C10 | |||
| 10 | 211.1 | C=O | - | - |
| 11 | 38.9 | CH2 | 2.46 m (ax) | C10 |
| 2.45 m (eq) | C12, C7a, C10 | |||
| 12 | 34.3 | CH2 | 2.10 m (ax) | C9, C7, C7a, C3a, C10 |
| 2.00 m (eq) | C9, C7a, C3a, C10 | |||
| Methylenedioxy | 100.9 | CH2 | 5.89 d ( | C1,C2 |
| 5.86 d ( | C1,C2 |
Figure 2Key HMBC (→) and COSY (▬) correlations of litsericinone (2).
13C-NMR (150 MHz), 1H-NMR (600 MHz) and HMBC spectral data of 8,9,11,12-tetrahydromecambrine (3) in CDCl3 (δ in ppm, J in Hz).
| Position | 13C (δ, CDCl3) | Type | 1H ( | HMBC (2 |
|---|---|---|---|---|
| 1 | 140.7 | Cq | - | - |
| 1a | 134.3 | Cq | - | - |
| 1b | 124.5 | Cq | - | - |
| 2 | 148.2 | Cq | - | - |
| 3 | 106.5 | CH | 6.49 s | C1a, C1, C2,C4 |
| 3a | 126.9 | Cq | - | |
| 4 | 27.4 | CH2 | 2.92 (m) ax | C1b, C5 |
| 2.72 (m) eq | C1b, C1a, C3 | |||
| 5 | 55.0 | CH2 | 3.09 (m) ax | C1b, C4, NCH3, C6a |
| 2.45 (m) eq | ||||
| 6a | 65.7 | CH | 3.30 br s | - |
| 7 | 44.5 | CH2 | 2.59 (m) ax | C3a, C1a, C8, C7a, C6a |
| 1.75 (m) eq | C8, C12, C7a, C6a | |||
| 7a | 46.0 | Cq | - | - |
| 8 | 34.6 | CH2 | 2.14 (m) ax | C3a, C12, C7 |
| 2.02 (m) eq | C3a, C12, C7a | |||
| 9 | 39.0 | CH2 | 2.47 (m) | C8, C11, C7a |
| C8, C11, C7a | ||||
| 10 | 211.7 | C=O | - | - |
| 11 | 38.6 | CH2 | 2.70 (m) ax | C12, C7a |
| 2.43 (m) eq | C12, C7a | |||
| 12 | 36.5 | CH2 | 2.50 (m) ax | C8, C11, C7 |
| 1.93 (m) eq | C3a, C8, C11, C7a | |||
| N-CH3 | 43.5 | CH3 | 2.39 s | C5, C6a |
| Methlenedioxy | 100.6 | CH2 | 5.88 | C1, C2 |
| (O-CH2-O) | 5.83 | C1, C2 |
Figure 3Key HMBC (→) and COSY (▬) of 8,9,11,12-tetrahydromecambrine (3).
13C-NMR (150 MHz), 1H-NMR (600 MHz) and HMBC spectral data of hexahydromecambrine A (4) in CDCl3 (δ in ppm, J in Hz).
| Position | 13C (δ, CDCl3) | Type | 1H ( | HMBC (2 |
|---|---|---|---|---|
| 1 | 148.1 | Cq | - | - |
| 1a | 129.0 | Cq | - | - |
| 1b | 131.0 | Cq | - | - |
| 2 | 140.8 | Cq | - | - |
| 3 | 105.9 | CH | 6.46 (s) | C1, C2,C4 |
| 3a | 124.0 | Cq | - | - |
| 4 | 27.3 | CH2 | 2.93 (m) ax | C5 |
| 2.71 (m) eq | C3a | |||
| 5 | 54.9 | CH2 | 3.11 (m) ax | C3a, C6a |
| 2.46 (m) eq | ||||
| 6a | 65.7 | CH | 3.26 (m) | - |
| 7 | 44.3 | CH2 | 2.44 (m) ax | C1a |
| 1.58 (m) eq | C12, C9 | |||
| 7a | 46.6 | Cq | - | - |
| 8 | 30.2 | CH2 | 2.03 (m) ax | C7a, C10 |
| 1.54 (m) eq | C12, C7a, C10 | |||
| 9 | 31.7 | CH2 | 2.41 (m) ax | |
| 1.46 (m) eq | C8, C7a, C10 | |||
| 10 | 67.1 | CH | 4.00 br, m | |
| 11 | 31.0 | CH2 | 1.75 (m) | C12, C7a, C10 |
| 12 | 29.7 | CH2 | 1.25 (m) | |
| N-CH3 | 43.2 | CH3 | 2.39 (s) | C5, C6a |
| (OCH2O) | 100.5 | CH2 | 5.90 ( | C1, C2 |
| 5.86 ( | C1, C2 |
Figure 4Key HMBC (→) and COSY (▬) of hexahydromecambrine A, (4).
The IC50 values of compounds 1–4 and positive control on the MCF7 and HepG2 cell lines.
| Compounds | IC50 (µg/mL) at 24 h | |
|---|---|---|
| MCF7 | HepG2 | |
| 1 | 26 | 27 |
| 2 | 60 | 14 |
| 3 | >100 | 81 |
| 4 | >100 | 20 |
| Doxorubicin | 0.2 | 1.06 |
The inhibition zone diameter (in mm) of isolated compounds against selected bacteria.
| Sample | Inhibition diameter (mm ± SD) | ||||
|---|---|---|---|---|---|
|
| |||||
| (Gram +ve) | (Gram +ve) | (Gram +ve) | (Gram −ve) | (Gram −ve) | |
| 12.00 ± 0.00 | 13.33 ± 0.57 | 15.50 ± 0.57 | NI | NI | |
| NI | NI | NI | NI | NI | |
| NI | NI | NI | NI | NI | |
| nt | nt | nt | nt | nt | |
| 20.00 ± 0.00 | 13.66 ± 0.57 | 21.00 ± 0.00 | 21.33 ± 1.15 | NI | |
Note: (NI)—no inhibition observed, (nt)—not tested. Doses of the samples were 1 mg/mL per disc, Streptomycin sulfate 10 µg per disc. a—Positive control.